Brodalumab Provides Rapid Onset of Therapeutic Response for Patients With Moderate-to-Severe Psoriasis
Main Article Content
Keywords
Psoriasis, Drug effectiveness, Time to response, Biologics, Patient-reported quality of life, Moderate-to-severe psoriasis
References
2. Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. New England Journal of Medicine. 2015;373(14):1318-1328.
3. Blauvelt A, Papp KA, Lebwohl MG, et al. Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: a pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3). Journal of the American Academy of Dermatology. 2017;77(2):372-374.
4. Gordon KB, Kimball AB, Chau D, et al. Impact of brodalumab treatment on psoriasis symptoms and health‐related quality of life: use of a novel patient‐reported outcome measure, the Psoriasis Symptom Inventory. British Journal of Dermatology. 2014;170(3):705-715.
5. Wu JJ. Contemporary management of moderate to severe plaque psoriasis. The American Journal of Managed Care. 2017;23(21 Suppl):S403-S416.
6. Egeberg A, Andersen YMF, Halling‐Overgaard AS, et al. Systematic review on rapidity of onset of action for interleukin‐17 and interleukin‐23 inhibitors for psoriasis. Journal of the European Academy of Dermatology and Venereology. 2020; 34(1):39-46.
7. Blauvelt et al. Slides presented at: Annual Meeting of the American Academy of Dermatology; March 3-7, 2017; Orlando, FL.
8. Gottlieb AB, Gordon K, Hsu S, et al. Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials. Journal of the European Academy of Dermatology and Venereology. 2018;32(8):1305-1313.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.